RealPennies.com: Turning Pennies into dollars: (Pink Sheets: PSMH), (OTCBB: SYBD), (OTCBB: SLNH), (Pink Sheets: AUCI).
Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559
For more info: http://www.realpennies.com/PSMH.html
PSM Holdings, Inc. (Pink Sheets: PSMH) ( December 12, 2007) PrimeSource Mortgage, Inc. (PSMI) continues to open branches Nationwide. PSMI proudly announces the opening of an independently owned and operated PrimeSource Mortgage (PSM) office in Clovis, New Mexico. Rebecca Reid-Carlyle is the owner and operator of this new PSM branch.
Incorporated in 1991 in Texas, PrimeSource Mortgage, Inc. quickly became a leading mortgage company in the Southwest and is currently licensed in 25 states. One reason for the growth and success of this company is its commitment to personalized customer service embodied in the motto: We Walk You Home. Because the mortgage process is so complex and often confusing, the company has chosen to walk hand-in-hand with each client through the entire process.
PSM Holdings, Inc. (Pink Sheets: PSMH - News), the parent company, is now a publicly traded company; over-the-counter (OTC) shares became available in October 2005. Ron Hanna, Chairman of the Board, said, "We are excited about this because it offers our customers and staff the opportunity to own a part of our company."
For more info: http://www.realpennies.com/SYBD.html
Synthetic Blood International, Inc. (OTCBB: SYBD) (December 12, 2007) today announced its plan to finalize a Phase IIb clinical trial protocol with Oxycyte for the treatment of traumatic brain injury (TBI) at its Scientific Advisory Board (SAB) meeting scheduled for Thursday, December 13, 2007. Oxycyte is Synthetic Blood's proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute.
The proposed double blind, placebo-controlled Phase IIb trial is designed to compare Oxycyte with present-day advanced therapies in TBI, and is expected to enroll 120 to 150 patients at six major neurosurgery centers. The trial protocol was prepared by M. Ross Bullock, M.D., Ph.D., of the University of Miami Miller School of Medicine, Department of Neurosurgery. Dr. Bullock was a principal investigator on Synthetic Blood's Phase IIa pilot study with Oxycyte in TBI and currently serves on the Company's SAB.
Synthetic Blood also announced intentions to name additional members to its SAB at the December 13 meeting. Those candidates under review are primarily located at medical centers that may be involved with Oxycyte trials. Additionally, the SAB plans to develop a strategy for initiating supportive preclinical studies to explore the basic science of Oxycyte's oxygen delivery capabilities for the treatment of damaged brain tissue, and the effects of higher Oxycyte doses than have been used in previous studies, as well as the potential effects of administering second doses of Oxycyte.
"Our Phase IIb trial protocol design was developed to provide what we believe will be definitive results with Oxycyte as a therapeutic treatment for TBI," stated Dr. Bullock. "Positive data from the pilot study in TBI patients demonstrated that Oxycyte was more effective in increasing brain oxygen tension levels and impacting other brain chemistries that contribute to favorable clinical outcomes in TBI patients than breathing either 100 percent or 50 percent oxygen. If we see similar results in the larger patient population, we believe that it is likely that the government may deem Oxycyte immediately useful for battlefield settings."
"We are making headway in our development program with Oxycyte in TBI that will capitalize on the favorable results from our Phase IIa pilot study," said Robert Larsen, Interim President and CEO of Synthetic Blood. "Finalizing the protocol is an important step in the process to prepare for our Phase IIb trial protocol submission to the U.S. Food and Drug Administration."
For more info: http://www.realpennies.com/SLNH.html
Splinternet Holdings, Inc. (OTCBB: SLNH) (December 12, 2007) announced that it is entering the anti-terrorism market with a new radiation detection device and monitoring system which will provide early warning of the presence of radioactive materials of the type feared to be usable in dirty bombs.
Together with its development of a networked radiation detection device, Splinternet has entered into a cross-licensing and selling agreement with privately-held Vidiation, LLC, a development-stage company with a revolutionary technology to identify radioactive materials by analyzing streams of data from video surveillance systems. Vidiation launched its Vidiation-Radiation Analytics Detection System or V-RADS at the Fall 2007 ASIS conference, and plans to enter the market shortly. (www.vidiation.com) Vidiation is the developer of a software-based technology that detects the presence of radiation when it comes in range of a video surveillance camera. The gamma rays from threats such as "dirty bombs" strike an image sensor in the camera causing a detectable pattern of interference. As the data from the camera is examined by Vidiation's V-RADS software, this radiation pattern is detected and an ALERT is sent to the designated monitoring station. This is strictly a software solution, which doesn't require modification to the cameras.
The Splinternet device is more sensitive than the software/video camera solution, but it does not provide a video image of the monitored site, as the Vidiation system does. The two systems are wholly compatible and complementary.
Vidiation's software solution dovetails with Splinternet's existing VoIP infrastructure, and requires no additional commitment of capital or retrofitting of Splinternet's existing network. By leveraging its VoIP expertise, Splinternet has developed a small hardware-based radiation detection device to work in conjunction with Vidiation's software by functioning as a smart networked radiation detection node. Like Splinternet's VoIP solution, the combined Splinternet/Vidiation products will network using Ethernet technology and will be managed via a local LAN or the World Wide Web.
For more info: http://www.realpennies.com/AUCI.html
Auctions International Inc. (Pink Sheets: AUCI) ( December 12, 2007) a technology company that owns and markets proprietary software to enable real time online auctions of virtually any product or commodity for use by the wholesale market, issued a statement from President and CEO Doug Mann regarding yesterday's volume and price change in its common stock, "No material changes in the Company or management would warrant an increase in trading volume or the sudden drop in share price that occurred on December 10th."
Mann explains, "The selling pressure may have been caused by a confusion between our Company and Auctioncities.com, with whom we have no affiliation. Coincidentally, Auctioncities.com is also in the auctions business and trades on the pink sheets under the stock symbol AUCC, just one letter off from ours. Auctioncities.com indicated it would effect a 1-for-1000 reverse split on otcbb.com yesterday, and that this split would be effective today. We want to clarify we are unrelated companies to those who may have mistaken us for this company.
"Management would like to ensure shareholders that Auctions International Inc. is moving in a very positive direction. With our technology model, AUCI lets people sell, buy and advertise in real-time to close transactions quickly to take advantage of economic conditions, particularly the strong Canadian dollar, which is opening up new business opportunities in the U.S. Auctions International has completed extensive dealer testing of AutoBidLive and is now ready to take every dealer in North America live on the system. 2007 marked our entry into the commercialization phase of our technology platform, and management is very optimistic that 2008 will be a tremendous year of growth and increased shareholder value."
Read our full disclaimer at: http://www.realpennies.com
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on
http://www.realpennies.com/content/view/42
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited.
RealPennies .
Telephone: 1-800-940-6559
Matt /at/ realpennies.com
No comments:
Post a Comment